GEHC vs EW

For growth investors, Edwards Lifesciences Corporation (EW) is the stronger pick with 11.

5% revenue growth year-over-year, versus 4. 8% for GE HealthCare Technologies Inc. (GEHC). GE HealthCare Technologies Inc. (GEHC) offers the better valuation at 13. 5x trailing P/E (12. 4x forward), making it the more compelling value choice. Analysts rate GE HealthCare Technologies Inc. (GEHC) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, GE HealthCare Technologies Inc.

(GEHC) is the cheapest at 13. 5x versus Edwards Lifesciences Corporation at 45. 2x. On forward P/E, GE HealthCare Technologies Inc. is actually cheaper at 12. 4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Edwards Lifesciences Corporation wins at 3. 89x versus GE HealthCare Technologies Inc. 's 19. 78x.

Over the past 5 years, GE HealthCare Technologies Inc.

(GEHC) delivered a total return of +2. 9%, compared to -10. 2% for Edwards Lifesciences Corporation (EW). Over 10 years, the gap is even starker: EW returned +133. 4% versus GEHC's +2. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Edwards Lifesciences Corporation (EW) is the lower-risk stock at 0.

65β versus GE HealthCare Technologies Inc. 's 1. 37β — meaning GEHC is approximately 109% more volatile than EW relative to the S&P 500. On balance sheet safety, Edwards Lifesciences Corporation (EW) carries a lower debt/equity ratio of 7% versus 94% for GE HealthCare Technologies Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Edwards Lifesciences Corporation (EW) is pulling ahead at 11.

5% versus 4. 8% for GE HealthCare Technologies Inc. (GEHC). On earnings-per-share growth, the picture is similar: GE HealthCare Technologies Inc. grew EPS 4. 8% year-over-year, compared to -73. 7% for Edwards Lifesciences Corporation. Over a 3-year CAGR, EW leads at 4. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Edwards Lifesciences Corporation (EW) is the more profitable company, earning 17.

7% net margin versus 10. 1% for GE HealthCare Technologies Inc. — meaning it keeps 17. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EW leads at 27. 0% versus 13. 4% for GEHC. At the gross margin level — before operating expenses — EW leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Edwards Lifesciences Corporation (EW) is the more undervalued stock at a PEG of 3. 89x versus GE HealthCare Technologies Inc. 's 19. 78x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, GE HealthCare Technologies Inc. (GEHC) trades at 12. 4x forward P/E versus 27. 5x for Edwards Lifesciences Corporation — 15. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GEHC: 36. 9% to $84. 00.

In this comparison, GEHC (0.

2% yield) pays a dividend. EW does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Edwards Lifesciences Corporation (EW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

65), +133. 4% 10Y return). Both have compounded well over 10 years (EW: +133. 4%, GEHC: +2. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GEHC is a mid-cap deep-value stock; EW is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.